Corrects EBITDA wording: the divested unit’s $17 million included overhead

The correction removes a favorable implication from the prior disclosure. Management previously said the divested Regulatory and Medical Writing business generated approximately $17 million of 2025 adjusted EBITDA excluding unallocated overhead; the corrected wording says the $17 million included those overhead costs, making the business’s underlying profitability look less strong than initially stated (Item 7.01 correction notice).

The headline figure itself did not change, but its meaning did. The filing does not revise quarterly revenue, earnings, cash flow, guidance, or transaction terms; it only corrects the description in the August 4, 2026 earnings call and presentation (Item 7.01 correction notice).

Net read: mildly unfavorable clarification, not a new operating event. Because the original wording overstated the segment’s implied profitability, the correction is negative relative to the information investors first received, but its impact is limited because no reported financial results or outlook were changed.